Back to top

cell-therapy: Archive

Zacks Equity Research

Vor Bio (VOR) Up on Positive Update From AML Cell Therapy Study

Vor Bio (VOR) stock gains after dosing the first patient in its phase I/II study of novel cell therapy, VCAR33 (Allogenic), to treat AML. The company extends its cash runway into the second half of 2025.

PBYINegative Net Change ADMAPositive Net Change ACADPositive Net Change VORNegative Net Change

Zacks Equity Research

Sana Bio (SANA) Stock Rallies 105% in 3 Months: Here's Why

Sana Bio (SANA) rallies 105% after the company reports encouraging pipeline progress with its candidates, SC291 and SC262, for oncology and autoimmune indications.

PBYINegative Net Change ADMAPositive Net Change ACADPositive Net Change SANAPositive Net Change